Business Context and Reporting Period
Company: pSivida Limited (Note: Request metadata listed "Eyepoint, Inc.", but the filing text is for pSivida Limited).
Filing Type: Form 20-F Annual Report.
Reporting Period: Fiscal year ended June 30, 2005.
Business Overview: pSivida is a global nanotechnology company developing BioSilicon, a biocompatible, biodegradable form of silicon for drug delivery, diagnostics, and tissue engineering. The company operates as a development-stage enterprise with no commercial products of its own generating significant revenue, relying instead on interest income and research collaborations. On December 30, 2005, pSivida completed the acquisition of Control Delivery Systems, Inc. (CDS), renamed pSivida Inc., which holds FDA-approved ophthalmic drug delivery products (Vitrasert and Retisert).
Key Financial Metrics (A-GAAP)
| Metric | Year Ended June 30, 2005 | Year Ended June 30, 2004 |
|---|---|---|
| Revenue from Ordinary Activities | A$828,976 | A$381,679 |
| Net Loss | (A$14,726,523) | (A$3,683,205) |
| Loss Per Share (Basic & Diluted) | (A$0.07) | (A$0.03) |
| Research & Development Expense | A$8,287,930 | A$7,011,666 |
| Cash and Cash Equivalents | A$12,892,061 | A$31,350,656 |
| Total Assets | A$82,035,313 | A$40,367,058 |
| Total Equity | A$79,987,614 | A$38,428,943 |
| Debt | None (as of June 30, 2005) | None |
Note: Revenue consists primarily of interest income on bank deposits (A$667,310 in 2005) and other income from research collaborations (A$161,666 in 2005). The company has no off-balance sheet financing.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 299.8% to A$14.7 million. This was primarily driven by the consolidation of pSiMedica (acquired in August 2004), resulting in the recognition of full costs, increased corporate administration expenses due to NASDAQ listing, and a significant unrealized foreign exchange loss of A$1.6 million.
- Revenue Growth: Revenue increased 117.2% to A$829,000, driven by higher interest income on increased cash balances and additional collaboration income.
- Balance Sheet Expansion: Total assets more than doubled to A$82 million, largely due to the recognition of intangible assets (licenses and patents) and goodwill from the pSiMedica acquisition.
- Cash Position: Cash reserves decreased by approximately A$18.5 million (from A$31.4 million to A$12.9 million) due to operating losses, investing activities (including the pSiMedica acquisition and facility construction), and foreign exchange impacts.
Guidance, Outlook, and Risks
Outlook and Guidance: The company expects to continue incurring net losses through at least 2007. Management anticipates that current cash levels will support operations until the second quarter of calendar year 2007. Pre-acquisition estimates for 2006 R&D spending were approximately A$13.5 million, but this is expected to increase significantly following the CDS acquisition.
Recent Transactions (Post-Period End):
- Acquisition of CDS: Completed December 30, 2005. Consideration included approximately 16 million ADSs (valued at ~A$118.8 million). This adds two FDA-approved products (Vitrasert and Retisert) to the portfolio.
- Convertible Note: Issued November 16, 2005, a US$15 million subordinated convertible note with an 8% interest rate and a conversion price of US$7.10 per ADS.
- PIPE Financing: Raised US$4.3 million in August 2005 via a private placement of ADSs and warrants.
Key Risks and Contingencies:
- Development Stage: No commercial products of pSivida's own (BioSilicon) are approved; reliance on clinical trial success (e.g., BrachySil for liver cancer) is critical.
- Regulatory Approval: Future revenue depends on FDA and foreign regulatory approvals for BioSilicon products and CDS products (e.g., Medidur for diabetic macular edema).
- Convertible Note Repayment: If the ADS price does not rise above the conversion price (US$7.10) by payment dates (starting Nov 2006), the company may be forced to repay principal in cash, which could strain liquidity.
- Integration Risk: Successful integration of CDS operations and technology is required to realize merger benefits.
- Internal Controls: Management disclosed that disclosure controls and procedures were ineffective as of June 30, 2005, due to insufficient accounting personnel with U.S. GAAP expertise.
Investor Verification Checklist
- Cash Runway: Verify if the US$15 million convertible note proceeds and remaining cash (A$12.9 million) are sufficient to fund operations through 2007 given increased R&D costs post-CDS acquisition.
- Convertible Note Terms: Confirm the likelihood of the ADS price exceeding US$7.10 to avoid cash repayment obligations in late 2006 and 2007.
- Integration Progress: Monitor the integration of CDS (pSivida Inc.) and the status of royalty payments from Bausch & Lomb for Vitrasert and Retisert.
- Internal Controls: Review subsequent filings for remediation of the ineffective disclosure controls and procedures identified in this report.
- Regulatory Milestones: Track the progress of BrachySil Phase IIb trials and Medidur Phase III trials, as these are critical for future revenue generation.
- Accounting Standards: Note the transition from A-GAAP to A-IFRS (effective July 1, 2005) and the restatement of U.S. GAAP amounts regarding deferred taxes.